Keytruda’s other indications, in bladder cancer and lung cancer depend upon the part of the body where a tumor originated. The solid tumor treated can be located in any part of the body. In fact, FDA granted accelerated approval to pembrolizumab (KEYTRUDA, Merck & Co.) for adult and pediatric patients. Merck says clearance was granted based on tumor response rates and durability of response, and that continued approval may depend upon data from confirmatory trials. “The improved responses seen with the Keytruda plus pemetrexed/carboplatin regimen are significant, and highlight the importance of finding new approaches that address the unmet needs of patients with metastatic nonsquamous non-small cell lung cancer. Today’s approval further supports our commitment to improve the lives of people with cancer,” Dr. Roger Perlmutter, president of Merck Research Laboratories, said.